Pharmacyte Biotech Inc (OTCMKTS:PMCB) COO, Dr. Gerald W. Crabtree, announced that his company is in talks with a leading expert team to help the company in its development of advanced therapies. As per reports, the team would be responsible for helping the company develop clinical trials for its treatments for cancer and diabetes. The company has been at the clinical stage for a very long time, despite initial success with its cell-in-a-box technology. The shareholders would hope that the new team can help the company move ahead. The announcement was made as part of an interview conducted by ‘PharmaVoice Magazine’.
Pharmacyte Biotech Inc (OTCMKTS:PMCB) recorded a 2.21% spike in its stock price to close at $0.0925, after experiencing a trade volume of 1.27 million on September 11.
Growblox Sciences Inc (OTCMKTS:GBLX) announced the appointment of a new CFO of the company, Mr. John Poss. The announcement came after Mr. Poss’s performance, as a consultant to the company, was reviewed. Growblox focuses its resources on development of novel technologies to help ease the process of cultivation for medical cannabis. The new appointment was made by the company CEO, Craig Ellins, and is being viewed as a move from being a technology developer to a cannabis cultivating and revenue generating company.
Growblox Sciences Inc (OTCMKTS:GBLX) saw a trade volume of 195,789 shares, to register a decline of 2.94%, during the September 11 session. The stock finally reached a close at a share value of $0.33.
Stellar Biotechnologies Inc (OTCMKTS:SBOTD) has announced that it would be trading under the symbol (OTCMKTS:SBOTD), instead of (OTCMKTS:SBOTF). The change would stay in place for a period of 20-days, after which the symbol would be changed back to its original form. The change has been imposed on the company as per FINRA’s regulations regarding reverse stock splits. Stellar Biotechnologies had announced that it has consolidated all of its outstanding and issued common shares, resulting in a reverse stock split.
Stellar Biotechnologies Inc (OTCMKTS:SBOTD) closed at a share price of $6.86, after trading 18,934 shares and registering a decline of 9.29% in its share value during the September 11 session.